|
|
Сonditions and diseases
AIDS/HIV ALS Alzheimer's Disease Anemia Anti-Aging Treatment Arterial Hypertension Cancer Diabetes Treatment Eye Diseases Idiopathic Encephalopathy Ischemic Heart Disease Liver Diseases MD Treatment Multiple Sclerosis Treatment Parkinson Treatment Rheumatoid Arthritis SMA Ulcerative Colitis. Crohn’s DiseaseALS Treatment
Amyotrophic lateral sclerosis (ALS, Charkot’s disease, Charkot’s sclerosis, in English-speaking countries – Lou Gehrig’s disease), or motor neuron disease, is a progressing illness that manifests as gradual weakening and atrophy of muscles and lasts for two to five years (in very rare cases – for seven years) with 100% fatal outcome. The clinical picture is compliant with lesion of central and peripheral motor neurons that results in bulbar syndrome as well as muscular atrophy in extremities and respiratory muscles.
Major manifestations of amyotrophic lateral sclerosis in patients include the following:
- weakness;
- muscle spasms;
- disorders of speech and swallowing;
- problems with keeping balance;
- spasticity;
- increased deep reflexes, or reflexogenic zone expansion;
- pathological reflexes;
- fibrillations;
- atrophy;
- hanging foot;
- respiratory disorders;
- paroxysms of involuntary laughter or cry;
- depression.
Treatment of ALS with stem cells
Indications for ALS treatment with stem cells include confirmed ALS diagnosis, disease progression, and lack of response to existing treatment methods. Prior to year 2000, contraindications to treatment included respiratory failure, grade III, artificial lung ventilation, dysphagia, and presence of gastric stoma. However, nowadays the clinic has experience of treating patients with the above-mentioned complications and disorders that allows for prolonging their life by more than five years.After transplantation of fetal stem cells, 67% of ALS patients note diminishing weakness, improvement of appetite and mood, decrease in intensity of fasciculations and spasticity. Within two months after transplantation, increase of motion volume in extremities, decrease in muscular rigidity, normalization of reflexes, decrease in the number of fasciculation zones, better tolerability of daily chores, reduction in intensity of dysphagia and dysarthria (improvement of swallowing, articulation, and clarity in pronunciation of words) have been observed in 34% of patients. Stable positive clinical effect after treatment persists for three to six months.
About 48% of patients need to repeat the course of treatment during the year for retaining the attained positive results. In 25% of cases, patients need periodic transplantations of stem cells every 1.5–2 years. Duration of the ALS treatment course at EmCell clinic, as a rule, totals 2 days.
Transplantation of fetal stem cells does not combat the immediate cause of the disease (to date, the exact cause of disease has not been found); however, it exerts substantial influence on links of the pathological process and slows down disease progression. Transplantation of fetal stem cells improves the quality of life of ALS patients and their ability to work, and prolongs their life.
Fetal stem cells in amyotrophic lateral sclerosis (poster presentation)
English, pdf, 930 kb
Appendix
Experience of ALS treatment at EmCell clinicFetal stem cells in amyotrophic lateral sclerosis (poster presentation)
English, pdf, 930 kb
Comments
News and articles about ALS treatment
Improved Survival in ALS Patients with Mild Obesity
08 June 2011
The study of over 400 ALS patients conducted at Massachusetts General Hospital has shown that mildly obese patients survived longer compared to patients with normal weight, or those underweight or overweight.
08 June 2011
The study of over 400 ALS patients conducted at Massachusetts General Hospital has shown that mildly obese patients survived longer compared to patients with normal weight, or those underweight or overweight.
Amyotrophic lateral sclerosis and smoking: correlation is discovered
16 April 2011
The scientists of the Harvard School of Public Health revealed that cigarette smoking may elevate risk to get amyotrophic lateral sclerosis (ALS).
16 April 2011
The scientists of the Harvard School of Public Health revealed that cigarette smoking may elevate risk to get amyotrophic lateral sclerosis (ALS).
Wrong location of a key protein in neuron causes amyotrophic lateral sclerosis
19 March 2011
Researchers from the University of California and San Diego School of Medicine found that the absence of a key protein TDP-43 in nucleus and its concurrent accumulation in cytoplasm play role not only in ALS pathogenesis but also in the development of other neurodegenerative diseases.
19 March 2011
Researchers from the University of California and San Diego School of Medicine found that the absence of a key protein TDP-43 in nucleus and its concurrent accumulation in cytoplasm play role not only in ALS pathogenesis but also in the development of other neurodegenerative diseases.
Canadian scientists conducted the first large-scale genetic research of ALS
12 February 2011
The team of Canadian scientists from the University of Montreal studied amyotrophic lateral sclerosis (ALS) patients’ genes in order to identify the cause of the disease. The study identified several promising novel genes for ALS.
12 February 2011
The team of Canadian scientists from the University of Montreal studied amyotrophic lateral sclerosis (ALS) patients’ genes in order to identify the cause of the disease. The study identified several promising novel genes for ALS.